Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ProShares Ultra Nasdaq Biotechnology (BIB)

73.18
BATS BZX Real-Time Price
As of 10:09am ET
 -2.83 / -3.72%
Today’s Change
42.50
Today|||52-Week Range
106.10
+16.62%
Year-to-Date

Investment Objective

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index ®. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

No recent news for ProShares Ultra Nasdaq Biotechnology.

Performance

1 month-21.05% 3 years+74.16%
3 months-14.22% 5 years+70.38%
1 year+42.56% Since inception+53.58%
Data through 09/01/2015

Quote Details

Previous close$76.01
Open day’s range72.00 – 75.05
Net asset value (NAV)81.09 (08/28/2015)
Daily volume357,861
Average volume (3 months)873,982
Data as of 10:09am ET, 09/01/2015

Peer Comparisonvs. Trading-leveraged equity ETFs

 BIBCategory
Performance 5-yr return+70.38%+21.46%
Expense Gross exp ratio1.08%0.89%
Risk 5 year sharpe ratio1.80--
Net assets$1.0B$173.4M
Average market cap----
Average P/E----
Dividend / Share--0.21%

Competitors

SFLA iPath® Long Extended S&P 500® TR Index...
ROLA iPath® Long Extended Russell 1000® TR ...
SSO ProShares Ultra S&P500

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 67.07%
-- 27.88%
-- 8.89%
-- 7.64%
-- 5.76%
-- 5.10%
GILD Gilead Sciences5.07%
BIIB Biogen4.95%
CELG Celgene4.92%
AMGN Amgen4.78%

Partner Offers